Copyright
©2011 Baishideng Publishing Group Co.
World J Gastroenterol. May 14, 2011; 17(18): 2302-2314
Published online May 14, 2011. doi: 10.3748/wjg.v17.i18.2302
Published online May 14, 2011. doi: 10.3748/wjg.v17.i18.2302
Pts. | Push ERCP-/DBE-ERCP | Sedation | X-ray | Procedure Time (min) | |||
Procedures | Therapy | Dose (mg) | Drug | Time (min) | Dose (103 cGy/cm2) | ||
1 | 7 | Ostium incision (snare, papillotome) dilation, 2 stents inserted, regular change of 2 stents/1 yr | 12.8 ± 3 132 ± 31 | Midazolam Pethidine | 19 ± 11 | 3.4 ± 2 | 122 ± 158 |
2 | 1 | Not successful, re-operation | 10.0 | Midazolam | 3.3 | 1.0 | 82 |
100 | Pethidine | ||||||
120 | Butylscopolamine | ||||||
3 P | 3 | Ostium incision (papillotome), dilation, stent insertion, regular change of stent/1 yr | 15.0 ± 1 | Midazolam | 7.5 ± 7 | 1.8 ± 1.9 | 115 ± 79 |
125 ± 35 | Pethidine | ||||||
40 | Butylscopolamine | ||||||
4 P | 4 | Stent insertion, regular change of stent/1 yr | 12 ± 2 | Midazolam | 20 ± 29 | 3.1 ± 1.6 | 110 ± 171 |
137 ± 25 | Pethidine | ||||||
5 | Diazepam | ||||||
5 | 2 | Not successful, PTCD | 12 ± 1 | Midazolam | 2.8 ± 1 | 4.0 ± 0.2 | 77 ± 11 |
150 | Pethidine | ||||||
5 | Diazepam | ||||||
40 | Butylscopolamine | ||||||
6 P | 2 | Stent insertion, closure of bile duct leakage | 7.8 ± 0.4 | Midazolam | 4.0 ± 1 | 0.4 ± 0.1 | 135 ± 71 |
100 | Pethidine | ||||||
7 | 9 | Ostium incision (papillotome), 2 stents inserted, regular change of stents/1 yr | 1691 ± 867 | Propofol | 7.1 ± 6 | 1.8 ± 2.4 | 168 ± 131 |
135 ± 74 | Pethidine | ||||||
40 | Butylscopolamine | ||||||
8 | 4 | Bougienage pancreaticojejunostomy, stent insertion into pancreatic duct and pseudocyst; normal hepatico-jejunostomy | 13.3 ± 2 | Midazolam | 11.8 ± 9 | 2.0 ± 2 | 161 ± 92 |
158 ± 38 | Pethidine | ||||||
40 ± 28 | Butylscopolamine | ||||||
9 | 1 | Normal hepaticojejunostomy | 14 | Midazolam | 10.1 | 0.5 | 91 |
150 | Pethidine | ||||||
10 | 4 | 3 stents inserted, one change of 2 stents | 11.2 ± 5 | Midazolam | 12.6 ± 9 | 0.6 ± 0.4 | 61 ± 12 |
133 ± 28 | Pethidine | ||||||
11 | 4 | Insertion nasobiliary probe, dilation, stone extraction, insertion of stent | 9.5 ± 1 | Midazolam | 8.1 ± 2 | 0.7 ± 0.4 | 61 ± 22 |
125 ± 35 | Pethidine | ||||||
20 | Butylscopolamine | ||||||
12 | 8 | Bougienage, papillotomy, papilla dilation 8-10mm, stent insertion, regular change of stents/18 months | 1082 ± 476 | Propofol | 14 ± 8 | 3.1 ± 1.8 | 113 ± 97 |
156 ± 77 | Pethidine | ||||||
47 ± 11 | Butylscopolamine | ||||||
13 | 3 | Stent insertion, regular change of stent unsuccessful due to progredient papilla tumor, PTCD | 10.8 ± 3 | Midazolam | 13 ± 4 | 5.9 ± 2.9 | 177 ± 61 |
91 ± 52 | Pethidine | ||||||
40 ± 28 | Butylscopolamine | ||||||
14 | 2 | Not successful, PTCD | 25 ± 7 | Midazolam | 5.4 ± 1 | 0.8 ± 0.1 | 155 ± 21 |
175 ± 35 | Pethidine | ||||||
15 | 2 | Not successful, PTCD | 7.8 ± 3 | Midazolam | 5.9 ± 2 | 1.5 ± 0.3 | 122 ± 46 |
100 ± 25 | Pethidine | ||||||
40 | Butylscopolamine | ||||||
16 | 1 | Ostium incision (papillotome), 2 stents inserted (perforation) | 14 | Midazolam | 15.7 | 1.7 | 155 |
150 | Pethidine | ||||||
5 | Diazepam | ||||||
17 | 5 | Papillotomy*, bougienage, nasobiliary probe; insertion of 2 stents, regular change of 2 stents/9 mo | 16.8 ± 4 | Midazolam | 11.6 ± 11 | 2.5 ± 2.6 | 198 ± 98 |
210 ± 74 | Pethidine | ||||||
16.7 ± 10 | Diazepam | ||||||
30 ± 11 | Butylscopolamine | ||||||
18 | 1 | Stone extraction | 19 | Midazolam | 24.4 | 5.3 | 178 |
200 | Pethidine | ||||||
19 | 4 | Extraction sludge & blood coagel, insertion nasobiliary probe, extraction of percutaneous drainage & insertion of 2 stents (rendezvous), regular change of 2 stents/ 9 mo | 13 ± 1 | Midazolam | 9.7 ± 9 | 2.0 ± 1.8 | 82 ± 31 |
116 ± 28 | Pethidine | ||||||
5 ± 5 | Diazepam | ||||||
20 | 4 | Papillotomy, stent insertion pancreatic duct, regular change of stent/6 mo, hemostasis with injection therapy | 695 ± 275 | Propofol | 8.7 ± 1 | 0.7 ± 0.4 | 61 ± 13 |
75 ± 50 | PSSSethidine | ||||||
70 ± 14 | Butylscopolamine | ||||||
21 | 3 | Insertion of 2 stents, regular change of 2 stents/6 mo | 12 ± 1.8 | Midazolam | 15 ± 7 | 4.5 ± 1.9 | 185 ± 32 |
158 ± 62 | Pethidine | ||||||
22 | 1 | Papillotomy, insertion of 2 stents | 19 | Midazolam | 17.2 | 4.5 | 113 |
200 | Pethidine | ||||||
40 | Butylscopolamine | ||||||
23 | 1 | Not successful, PTCD | 16 | Midazolam | 0.6 | 0.2 | 63 |
50 | Pethidine | ||||||
20 | Butylscopolamine | ||||||
24 | 2 | Stent insertion | 17.5 ± 2 | Midazolam | 18.9 ± 15 | 5.6 ± 2.8 | 150 ± 61 |
100 ± 70 | Pethidine | ||||||
25 P | 3 | Stone/sludge extraction, dilation, biliary metal stent and malignant bile duct stricture, stent insertion, regular change of stent/9 mo | 9 ± 4 | Midazolam | 12.9 ± 2 | 3.3 ± 1.1 | 54 ± 12 |
200 ± 65 | Pethidine | ||||||
26 | 2 | Ostium incision (papillotome), bougienage, stent insertion | 7 ± 4 | Midazolam | 4.5 ± 2 | 1.2 ± 0.6 | 61 ± 23 |
75 ± 35 | Pethidine | ||||||
40 ± 20 | Butylscopolamine | ||||||
27 | 3 | Papillotomy, extraction of percutaneous drainage and insertion of 2 stents (rendezvous) | 5.7 ± 1 | Midazolam | 5.0 ± 1 | 1.0 ± 0.1 | 71 ± 12 |
83 ± 28 | Pethidine | ||||||
40 | Butylscopolamine | ||||||
28 | 1 | Not successful, PTCD | 5 | Midazolam | 2.1 | 0.6 | 109 |
50 | Pethidine | ||||||
29 | 2 | Papillotomy, bougienage, stent insertion | 9 ± 2 | Midazolam | 9.2 ± 2 | 4.4 ± 0.3 | 113 ± 21 |
150 ± 25 | Pethidine | ||||||
30 | 1 | Sludge extraction, insertion nasobiliary | 2.5 | Midazolam | 16.4 | 7.8 | 123 |
50 | Pethidine | ||||||
31 | 2 | Papillotomy, stone extraction, extraction of percutaneous drainage and insertion of stent (rendezvous) | 7 ± 2 | Midazolam | 2.2 ± 0.5 | 1.9 ± 0.4 | 96 ± 31 |
100 ± 25 | Pethidine | ||||||
80 | Butylscopolamine | ||||||
32 P | 1 | Stent insertion | 10 | Midazolam | 27.1 | 7.9 | 161 |
200 | Pethidine | ||||||
20 | Butylscopolamine | ||||||
33 | 2 | Not successful, PTCD diagnostic pancreatography, extraction of percutaneous drainage with both ostium incision and insertion of 2 stents (rendezvous) | 12 ± 5 | Midazolam | 10.6 ± 9 | 3.3 ± 2.5 | 97 ± 80 |
150 ± 70 | Pethidine | ||||||
40 ± 28 | Butylscopolamine | ||||||
34 P | 3 | Insertion of 2 stents, regular change of stents/12 mo | 10 ± 7 | Midazolam | 19.9 ± 10 | 3.6 ± 2.3 | 98 ± 33 |
183 ± 124 | Pethidine | ||||||
10 ± 5 | Diazepam | ||||||
20 ± 20 | Butylscopolamine | ||||||
35 | 1 | Not successful, PTCD diagnostic pancreatography | 11 | Midazolam | 0.3 | 0.1 | 86 |
150 | Pethidine | ||||||
40 | Butylscopolamine | ||||||
36 | 1 | Normal choledochojejunostomy | 7 | Midazolam | 2.1 | 1.8 | 51 |
50 | Pethidine | ||||||
20 | Butylscopolamine | ||||||
37 | 1 | Ostium incision (papillotome), insertion of 2 stents | 8.5 | Midazolam | 4.4 | 2.0 | 72 |
150 | Pethidine | ||||||
Pts overall | Total number PE/DBE | Mean sedation dose per examination | Total x-ray time | Total x-ray dose | Total examination time | ||
37 | 16 PE 86 DBE | 11.7 ± 2.8 | Midazolam | 9.0 ± 5.5 | 2.5 ± 1.3 | 111 ± 54 | |
124 ± 45 | Pethidine | ||||||
20 ± 20 | Butylscopolamine | ||||||
1156 ± 593 | Propofol |
- Citation: Raithel M, Dormann H, Naegel A, Boxberger F, Hahn EG, Neurath MF, Maiss J. Double-balloon-enteroscopy-based endoscopic retrograde cholangiopancreatography in post-surgical patients. World J Gastroenterol 2011; 17(18): 2302-2314
- URL: https://www.wjgnet.com/1007-9327/full/v17/i18/2302.htm
- DOI: https://dx.doi.org/10.3748/wjg.v17.i18.2302